The type of stem cell called iPSCs (induced Pluripotent Stem Cells) has worked its way into potential therapies for virtually every part of your body, and the research is being done in thousands of labs around the world. In the less than 15 years since Shinya Yamanaka created the first iPSCs this versatile type of stem cell has become a favorite candidate for creating tissues to repair or replace parts of our bodies that just arent working right.
These cellscalled pluripotent because they can make any tissueresult from delivering and briefly turning on in adult cells three or four genes that normally only have a role in embryos. That creates the iPSCs that can then be given genetic or chemical instructions to become any needed tissue. Theoretically iPSCs can be made from any cell in your body, but the efficiency of making them and their quality varies based on the cells you start with. The blood cells stored in the GoodCell personal biobank include one type of cell, the endothelial progenitor cell, that is particularly efficient at making more genetically stable iPSCs. And because that cell spends most of its time deep inside your body it has fewer sun-induced mutations than other cells. Cell banking these types of cells as early as possible preserves your best cells with the fewest age-generated mutations, making cell storage a potential means for taking advantage of cell therapies in the future.
Proud of native son Yamanakas Nobel-Prize-winning accomplishment, the Japanese government and research institutions have pushed the fastest into iPSC clinical trials. Teams there are testing therapies for heart failure, the leading cause of vision loss in adults, Parkinsons disease, arthritic knees and several other conditions. World-wide there are more than 100 clinical studies using iPSCs.
Some of the Japanese trials use cells made from the patient and some use cells from banks of cells curated to be compatible with the majority of the populations immune systems in Japan. This is relatively easy in the genetically more homogenous population there, unlike in the U.S. Even then patients tend to be given potentially dangerous immune suppressive drugs to protect the donor tissue from rejection. In this country, scientists increasingly see the need to make sure their work reflects the wide genetic diversity of our population. Getting immunologically compatible donor cells here is much more difficult, leading many researchers here to work on personalized therapies made from individuals own cells, like those stored in the GoodCell personal biobank.
The National Institutes of Health has a clinical trial underway for the same vision loss as the Japanese trial, called Age-related Macular Degeneration. A Boston team treated a Parkinsons disease patient with good results, and the Food and Drug Administration in the past month has given approval for large trials in Parkinsons and diabetes. Other teams have trials underway or are in final stage of planning for heart failure, spinal cord injury, endometriosis, cartilage defects and several other conditions.
Bioprinting has emerged as one of the most exciting new fields in biotechnology. Its very much as it sounds. A printer that uses cells as ink. Using various types of cells created by those chemical and genetic guides given to iPSCs, researchers can lay down complex layers of different cells and tissues. The technology recently produced functional kidney tissue following on success with several other organs. Each organ immediately becomes a tool for studying the underlying causes of the diseases afflicting the cell donors, but also begins to create a path to replacement of tissue and organs.
Many other tissue engineering advances have come from the simple concept of scaffolds, giving the new cells the structure and shape they need to create the desired tissue. A team in London recently used a scaffold to build a whole functioning thymus. That little discussed tiny gland helps mature our immune system T cells so they can get to work, and it is suddenly a very big deal during the COVID pandemic. A poorly functioning thymus probably accounts for some of the more severe outcomes with the disease.
While it may sound relatively simple to nudge a gene or add a chemical and get iPSCs to turn into nerves, getting that right recipe has become one of the toughest parts of developing iPSC-derived therapies. But several groups in the past few months made major advances simplifying the task, with one team publishing a virtual recipe book available to scientists around the world for improving the creation of any tissue.
Then comes the task of getting the new cells to where they are needed. That final step, gearing up manufacturing to serve the thousands of patients needing therapies, is now being supported by a vast new industry that saw that saw a 20 percent increase in capital investment last year and is expected to reach $10 billion by 2030. The FDA expects 10 to 20 new cell and gene therapies to be approved each year by 2025.
Two members of GoodCells scientific advisory board (SAB) are among the worlds leaders in harnessing the power of iPSCs to understand disease and look for ways to intervene either with cell therapies or traditional drugs therapies. For many diseases, researchers have had a hard time figuring out what is really causing the malfunction. But by creating iPSCs from people with the disease, they can create, for example, nerves in a petri dish that have all the attributes of ALS (amyotrophic lateral sclerosis or Lou Gehrigs disease).
Kevin Eggan, GoodCell SAB member and professor at the Harvard Stem Cell Institute, a few years ago developed such a model for ALS and found the patients nerves die from the exhaustion of over firing. Subsequently they tested a drug known to calm over-active nerves and in a recent phase 2 trial it improved nerve function in ALS patients. Similarly, SAB member Joseph Wu from Stanford has used iPSC-derived heart cells from patients to uncover the basis of various cardiomyopathies and other cardiac conditions, and he expects to create paths to individualized therapies.
Having this world leading expertise on our SAB helps GoodCell remain prepared to make the best possible use of the cells stored in your Personal Biobank.
Read more:
Regenerative Medicine Bets on iPS Stem Cells - GoodCell
- Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing ... - PR Newswire - April 24th, 2024
- SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ... - PR Newswire - April 20th, 2024
- Detection of biomagnetic signals from induced pluripotent stem cell-derived cardiomyocytes using deep learning with ... - Nature.com - April 1st, 2024
- Researchers discover new microRNA-regulated pathway to boost iPS cell-derived platelet production - Phys.org - March 30th, 2024
- Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks - Nature.com - March 28th, 2024
- Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock - The Scientist - March 13th, 2024
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy - Nature.com - March 3rd, 2024
- Breaking through new research barriers with iPSC technology - News-Medical.Net - February 15th, 2024
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 12th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 12th, 2024
- Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for ... - Nature.com - December 23rd, 2023
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming - Nature.com - December 15th, 2023
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 13th, 2023
- CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes ... - Nature.com - December 7th, 2023
- World Hindu Congress 2023: Know all about the sessions and speakers - Organiser - November 23rd, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS ... - Business Wire - November 21st, 2023
- Efficient protocol for the differentiation of kidney podocytes from ... - Nature.com - November 17th, 2023
- Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com - November 17th, 2023
- Study reveals the critical role of microglia in human brain development - Medical Xpress - November 15th, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through... - November 15th, 2023
- Who are the leading innovators in iPSCs for the pharmaceutical ... - Pharmaceutical Technology - November 7th, 2023
- Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous... - November 5th, 2023
- Systematic differences in discovery of genetic effects on gene ... - Nature.com - October 21st, 2023
- Pairwise biosynthesis of ion channels stabilizes excitability and ... - pnas.org - October 11th, 2023
- Scientists find multitude of genes associated with autism - The Statesman - October 9th, 2023
- Stem Cell Banking Market is Expected to Reach USD 16,474.30 ... - Digital Journal - October 7th, 2023
- Probing the individuality of cells and molecules - Open Access Government - October 5th, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Manchestertimes - October 3rd, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Business Wire - September 29th, 2023
- Less Funding to More Researchers Gets Nobel-level Results, Study ... - The Japan News - September 27th, 2023
- Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for ... - OncLive - September 20th, 2023
- DKMS BMST Foundation India and Kokilaben Hospital unite to spread awareness about the Importance of Stem Cell Donation on World Marrow Donor Day - APN... - September 18th, 2023
- Vitamin B6 is governed by the local compartmentalization of ... - Science - September 14th, 2023
- Dolly the sheep creator Ian Wilmut dies aged 79 - BBC - September 14th, 2023
- Scientist who created Dolly the sheep dies aged 79: Professor Sir Ian Wilmut passes away five years after reve - Daily Mail - September 11th, 2023
- The global kits market is expected to grow at a CAGR of 7.4% from ... - Digital Journal - September 8th, 2023
- Eterna Therapeutics Announces Initiation of Development Activities ... - PipelineReview.com - September 8th, 2023
- Tokyo: 100 Years of Urban Regeneration / Tokyo's Nihonbashi Area ... - The Japan News - August 31st, 2023
- Transcriptome-based prediction of drugs, inhibiting ... - Nature.com - August 30th, 2023
- From the birds and the bees to IVG - The Gauntlet - August 26th, 2023
- Breakthrough creates stem cells without any memories - Freethink - August 26th, 2023
- Aging impairs the neurovascular interface in the heart - Science - August 26th, 2023
- For This Venture Capitalist, Research on Aging Is Personal; 'Bob ... - The Wall Street Journal - August 22nd, 2023
- Unleashing Potential: Illuminating the Future of Healthcare through Revolutionary Induced Pluripotent Stem Cel - openPR - August 18th, 2023
- A 'memory wipe' for stem cells may be the key to better therapies - The Conversation - August 16th, 2023
- Erasing epigenetic 'memory' to improve the quality of stem cells - FierceBiotech - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Business Wire - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Valdosta Daily Times - August 11th, 2023
- Advancing Clinical Trials with iPSC-Derived Liver Organoids - Microbioz India - August 11th, 2023
- Activation of cAMP (EPAC2) signaling pathway promotes hepatocyte ... - Nature.com - August 1st, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapys Ability to Create New Skeletal... - July 30th, 2023
- Femtech in Japan: An Industry on the Rise - Femtech Insider - July 28th, 2023
- Association between enhanced carbonyl stress and decreased ... - Nature.com - July 28th, 2023
- Defects in early synaptic formation and neuronal function in Prader ... - Nature.com - July 27th, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of ... - Business Wire - July 25th, 2023
- Cure to Autism and Alzheimer's May Be in Space, Says 1st Brazilian Scientist who Will Be on The ISS - Folha de S.Paulo - July 25th, 2023
- Futurama's Resurrection Ruins The Perfect Ending (& Shows Must ... - Looper - July 25th, 2023
- University Of Massachusetts Amherst's Team Bags Honour Of 2023 Armstrong Fund For Science Award - India Education Diary - July 20th, 2023
- Scientists working on IVG, a new reproductive method that can make human babies in labs - IndiaTimes - July 19th, 2023
- Co-transplantation of autologous Treg cells in a cell therapy for ... - Nature.com - July 13th, 2023
- Magic Valley and Biocellion Join Forces to Improve Bioreactor Tech ... - vegconomist - the vegan business magazine - July 13th, 2023
- IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ... - Tullahoma News and Guardian - July 10th, 2023
- Hitachi : forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT - Marketscreener.com - July 6th, 2023
- Cell therapy limitations with iPS-based multi-cell therapeutics - Drug Target Review - July 6th, 2023
- Remembering Dolly- The Clone Sheep On Her Birth Anniversary - Free Press Journal - July 4th, 2023
- Labs and Translational Research - UMass Medical School - June 28th, 2023
- Cellusion raises 2.83B series C round to progress iPS cell-derived ... - BioWorld Online - June 14th, 2023
- Japan-based Fujifilm introduces first-of-its-kind human iPSC-derived ... - BSA bureau - June 6th, 2023
- ALS: Parkinson's drug ropinirole may be an effective treatment - Medical News Today - June 4th, 2023
- Scientists predict lab-grown babies in five years - Kidspot - June 4th, 2023
- Lab-grown babies could become a reality within five years - Earth.com - May 26th, 2023
- Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month - ZAWYA - May 24th, 2023
- Long-Awaited Ax-2 Mission Launches, Heads to Space Station - AmericaSpace - May 22nd, 2023
- Eterna Therapeutics and Factor Bioscience Announce New Data on ... - GlobeNewswire - May 17th, 2023
- Research Assistant job with UNITED ARAB EMIRATES ... - Times Higher Education - May 10th, 2023
- Regulation of synaptic connectivity in schizophrenia spectrum by ... - Nature.com - April 29th, 2023
- Researchers Discover Key Role of Glucose in Brain Activity - Laboratory Equipment - April 25th, 2023
- Structure of Huntington's Protein Revealed - Technology Networks - April 21st, 2023
- Study of brain immune cell infection may explain long COVID ... - NHK WORLD - April 19th, 2023
- The Mechanism That Regulates Activity of Memory Gene - Neuroscience News - April 19th, 2023
Recent Comments